Pharvaris (NASDAQ:PHVS) Insider Peng Lu Sells 15,000 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Peng Lu sold 15,000 shares of the firm’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $30.24, for a total transaction of $453,600.00. Following the sale, the insider owned 66,083 shares of the company’s stock, valued at approximately $1,998,349.92. The trade was a 18.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Peng Lu also recently made the following trade(s):

• On Wednesday, April 29th, Peng Lu sold 3,733 shares of Pharvaris stock. The shares were sold at an average price of $30.06, for a total value of $112,213.98.
• On Thursday, April 23rd, Peng Lu sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total value of $3,003.00.
• On Wednesday, April 22nd, Peng Lu sold 7,001 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $210,380.05.

Pharvaris Stock Down 5.1%

Shares of Pharvaris stock opened at $29.44 on Friday. Pharvaris N.V. has a 52 week low of $14.59 and a 52 week high of $31.14. The business’s fifty day simple moving average is $27.62 and its 200-day simple moving average is $26.03. The firm has a market cap of $1.93 billion, a PE ratio of -8.74 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Friday, April 3rd. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.15). As a group, equities analysts expect that Pharvaris N.V. will post -3.19 earnings per share for the current year.

Key Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Insiders still retain large, meaningful stakes after the sales, which can indicate alignment with shareholders and limit the likelihood of continued big disposals. Examples: director Johannes Schikan remains a large shareholder (~355k shares after sales) and others still hold six‑figure stakes. SEC Filing
• Neutral Sentiment: Commentary noting that director sales may matter less than upcoming company catalysts — suggests investors should watch near‑term clinical/regulatory milestones rather than focus only on the trades. For Pharvaris Investors, the Director’s Sale Matters Less Than What’s Coming Next
• Negative Sentiment: Anne Lesage sold multiple blocks (3,700; 19,200; 21,700 shares) across April 29–30 at ≈$30.08–$30.26, reducing her position by as much as ~27.8% in filings and generating >$1.34M in proceeds — a signal that prompted selling pressure. SEC Filing
• Negative Sentiment: Peng Lu executed two sales (3,733 and 15,000 shares) on April 29–30 at ≈$30.06–$30.24, cutting ownership by up to ~18.5% and raising roughly $565.8k — another substantial insider liquidity event. SEC Filing
• Negative Sentiment: Director Johannes Gerardus Chri Schikan sold two blocks (3,830 and 29,070 shares) on April 29–30 at ≈$30.07–$30.32, a ~7.6% cut in his holdings and ~ $996.6k in disclosed proceeds — adding to the overall sell pressure. SEC Filing

Analyst Ratings Changes

Several brokerages have recently commented on PHVS. Wall Street Zen lowered Pharvaris from a “sell” rating to a “strong sell” rating in a research note on Monday, April 13th. Wolfe Research began coverage on Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a research note on Tuesday, March 3rd. Wedbush boosted their price objective on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Finally, Royal Bank Of Canada cut their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.73.

Institutional Investors Weigh In On Pharvaris

Institutional investors and hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new stake in shares of Pharvaris in the 4th quarter valued at $35,000. Barclays PLC purchased a new stake in shares of Pharvaris in the 4th quarter valued at $77,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Pharvaris in the 3rd quarter valued at $75,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Pharvaris in the 4th quarter valued at $86,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after buying an additional 783 shares during the period.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.